X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
LNZ101 is a fixed dose opthalmic solution of aceclidine (mAChRs agonist) & brimonidine (ADRA2 agonist), which is being evaluated for the treatment of presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: LNZ101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2024
Details:
The net proceeds will be used on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: LNZ101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Versant Ventures
Deal Size: $53.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 21, 2024
Details:
The combined will focus on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: LNZ101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Graphite Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 21, 2024
Details:
The combined will focus on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: LNZ101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: LENZ Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger November 15, 2023
Details:
The net proceeds will be used on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: LNZ101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Versant Ventures
Deal Size: $53.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 15, 2023
Details:
The Proceeds will enable LENZ to complete the development and registration and, pending approval, launch LNZ100 (aceclidine) and LNZ101 (aceclidine and brimonidine) in the United States.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: LNZ101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sectoral Asset Management
Deal Size: $83.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 07, 2023
Details:
Both LNZ100 (aceclidine), and LNZ101 (aceclidine + brimonidine) maintained statistical significance of three-line or greater improvement compared to vehicle for all timepoints including the last measured at 10 hours, 37% and 48% respectively.
Lead Product(s): Brimonidine Tartrate,Aceclidine Hydrochloride
Therapeutic Area: Ophthalmology Product Name: LNZ101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
Details:
The investment by RTW promise LENZ to emerge as a global leader based on its potential best-in-class aceclidine presbyopia eye drop. Aceclidine is a small molecule acetylcholine receptor agonist that causes pupil contraction, creating pinhole effect that improves near vision.
Lead Product(s): Aceclidine Hydrochloride
Therapeutic Area: Ophthalmology Product Name: LNZ100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: RTW Investments
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 13, 2022
Details:
Under the license agreement with Ji Xing Pharmaceuticals, LENZ will develop and commercialize LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine) for the treatment of presbyopia in Greater China.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: LNZ101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ji Xing Pharmaceuticals
Deal Size: $110.0 million Upfront Cash: $15.0 million
Deal Type: Licensing Agreement April 13, 2022
Details:
LENZ Therapeutics (formerly Presbyopia Therapies) is developing a proprietary eye drop formulation of aceclidine. Aceclidine is an NCE in the U.S. and has an established safety profile from its prior use in Europe for glaucoma.
Lead Product(s): Aceclidine Hydrochloride
Therapeutic Area: Ophthalmology Product Name: PRX-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Versant Ventures
Deal Size: $47.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 17, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
